Dr. Siegall worked at the Bristol-Myers Squibb Pharmaceutical Research Institute as a Senior Research Investigator from February 1991 to January 1995 and as a Principal Scientist from January 1995 to December 1997. Dr. Siegall has been the Chairman of Seattle Genetics, Inc. since March 2004. He filled in as Interim Chairman of Seattle Genetics Inc., since April 1, 2004. He has been a Director of Ultragenyx Pharmaceutical Inc. since January 30, 2014. He has been Director of Seattle Genetics Inc. since December 1997 and Alder Biopharmaceuticals Inc. since November 2005.
Dr. Siegall filled in as a Director of Washington Biotechnology and Biomedical Association (WBBA) and also on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance. He filled in as a Non Executive Director of Mirna Therapeutics, Inc. since January 30, 2013 until December 31, 2016.
From February 1988 to February 1991, Siegall was a Staff Fellow and Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr. Siegall has created 67 logical papers and holds nine licenses. He serves on the Editorial Board of three logical diaries and is an individual from the Board of Scientific Counselors for the Cancer Treatment Research Foundation. He was given the Pierce Award in 1995 for his endeavors in the field of focused poisons. In 2002, he was an Ernst and Young Pacific Northwest Entrepreneur of the Year grant finalist in the human services classification.
The goal of Seattle Genetics is promoting the health of society, which includes ensuring that all available medical tools used by healthcare professionals are available. Siegall’s concern for the health of others stems from both his passion for the field of genetics and watching his father struggle with cancer at a young age. Siegall earned a doctorate in Genetics prior to spending time working for Bristol-Myers Squibb, which is the reason Siegall lives in Seattle.